| A | B |
|---|
| 80% Burkitt lymphoma | t(2;8)(q11;q24) |
| 15% Burkitt lymphoma | t(8;22)(q24;q11) |
| 5% Burkitt lymphoma | t(8;14)(q24;q32) |
| Burkitt lymphoma | MYC |
| 90%-95% Chronic myelogenous leukemia | t(9;22)(q34;q11) |
| Chronic myelogenous leukemia | BCR-ABL |
| 10%-15% Acute lymphocytic leukemia | t(1;19)(q23;p13) |
| BCR-ABL | Acute lymphocytic leukemia |
| 3%-6% Acute lymphoblastic leukemia | t(1;19)(q23;p13) |
| Acute lymphoblastic leukemia | TCF3-PBX1 |
| ∼95% Acute promyelocytic leukemia | t(15;17)(q22;q11) |
| 10%-30% Chronic lymphocytic leukemia | t(11;14)(q13;q32) |
| Chronic lymphocytic leukemia | BCL1 |
| ∼100% Follicular lymphoma | t(14;18)(q32;q21) |
| Follicular lymphoma | BCL2 |
| cytoplasmic tyrosine kinase | ABL; CML |
| transcription factors | myc; Burkitt's |
| anti-apoptotic proteins | BCL2; chronic lymphocytic leukemia |
